NKTR (Nektar Therapeutics): Time to Pay Attention?

After finishing at $2.24 in the prior trading day, Nektar Therapeutics (NASDAQ: NKTR) closed at $2.27, up 1.34%. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 1510969 shares were traded. NKTR stock price reached its highest trading level at $2.3450 during the session, while it also had its lowest trading level at $2.2000.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Ratios:

Our goal is to gain a better understanding of NKTR by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.90 and its Current Ratio is at 7.10. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Goldman Downgraded its Neutral to Sell on April 18, 2022, while the target price for the stock was maintained at $3.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 16 when Zalevsky Jonathan sold 13,460 shares for $3.57 per share. The transaction valued at 48,052 led to the insider holds 313,663 shares of the business.

Wilson Mark Andrew sold 8,690 shares of NKTR for $31,023 on Nov 16. The Chief Legal Officer now owns 272,498 shares after completing the transaction at $3.57 per share. On Nov 16, another insider, Thomsen Jillian B., who serves as the Chief Financial Officer of the company, sold 11,095 shares for $3.57 each. As a result, the insider received 39,609 and left with 323,764 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 4.53 while its Price-to-Book (P/B) ratio in mrq is 1.03.

Stock Price History:

Over the past 52 weeks, NKTR has reached a high of $11.59, while it has fallen to a 52-week low of $1.99. The 50-Day Moving Average of the stock is 2.7962, while the 200-Day Moving Average is calculated to be 3.6704.

Shares Statistics:

The stock has traded on average 1.56M shares per day over the past 3-months and 1.06M shares per day over the last 10 days, according to various share statistics. A total of 187.64M shares are outstanding, with a floating share count of 185.37M. Insiders hold about 1.50% of the company’s shares, while institutions hold 94.80% stake in the company. Shares short for NKTR as of Oct 13, 2022 were 17.39M with a Short Ratio of 9.00M, compared to 17.59M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 9.28% and a Short% of Float of 14.24%.

Earnings Estimates

Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of -$0.29 and a low estimate of -$0.66, while EPS last year was -$0.7. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.29 and low estimates of -$0.44.

Analysts are recommending an EPS of between -$1.92 and -$2.4 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$1.07, with 10 analysts recommending between -$0.68 and -$1.52.

Revenue Estimates

10 analysts predict $22.61M in revenue for the current quarter. It ranges from a high estimate of $25.87M to a low estimate of $20.9M. As of the current estimate, Nektar Therapeutics’s year-ago sales were $24.92M, an estimated decrease of -9.30% from the year-ago figure. For the next quarter, 10 analysts are estimating revenue of $22.42M, a decrease of -10.40% less than the figure of -$9.30% in the same quarter last year. There is a high estimate of $25.87M for the next quarter, whereas the lowest estimate is $21M.

A total of 9 analysts have provided revenue estimates for NKTR’s current fiscal year. The highest revenue estimate was $98.15M, while the lowest revenue estimate was $88.1M, resulting in an average revenue estimate of $90.81M. In the same quarter a year ago, actual revenue was $101.91M, down -10.90% from the average estimate. Based on 10 analysts’ estimates, the company’s revenue will be $90.97M in the next fiscal year. The high estimate is $108M and the low estimate is $67.02M. The average revenue growth estimate for next year is up 0.20% from the average revenue estimate for this year.